Loading
Biohaven
A listed US drug company working across several diseases. In cancer it is testing two antibody-drug conjugates, drugs that carry a toxin to cancer cells, in early trials for advanced solid tumours including bladder cancer.
Also called: Biohaven Ltd.Biohaven Ltd
Overview
Biohaven Ltd. describes itself as working in immunology, obesity, neuroscience and oncology. Its oncology pipeline lists two antibody-drug conjugates in Phase 1b: BHV-1510, a Trop2-directed ADC tested alone and with a PD-1 antibody in advanced or metastatic epithelial tumours (NCT06384807, where it is named as previously PBI-410, with cemiplimab), and BHV-1530, an FGFR3-directed ADC for urothelial cancer and other tumours (NCT06874335, also listed as AMB302, alone and with cemiplimab). The rest of its pipeline covers extracellular protein degraders, Kv7 ion channel modulators, myostatin/activin inhibition, TRPM3 antagonism and TYK2/JAK1 inhibition. Biohaven Ltd. trades on the NYSE under BHVN according to its SEC filings.
Headquarters
New Haven, CT, US
Scorecard
All companies#429of 1706 companies, score 10
- phase 1/2 +2
- targets +4
- modalities +2
- registry trials +2
0 approved, 0 in phase 3, 2 earlier, 2 targets, 1 registry studies. Formula on the scorecards page.
Funding
All startupsPublic
Investors
Type
Biotech · NYSE: BHVN
Stage
Public
Website
Products
2Phase 1ADC
BHV-1510 is an experimental chemotherapy-delivering antibody being studied alone and with immunotherapy. Early response findings need confirmation in larger trials.
Phase 1Antibody-drug conjugate
BHV-1530 is an experimental antibody-drug conjugate from Biohaven, in phase 1 trials for urothelial cancer and other solid tumours.
Notes
- RA Capital's page records an acquisition announced in 2022 alongside the original IPO; that refers to the earlier Biohaven company, and this record covers the current Biohaven Ltd. (SEC former name Biohaven Research Ltd., 2022). The 2022 transaction itself was not read from a primary source and is not described here.
- Founding year of Biohaven Ltd. not stated on pages read.
- BHV-1530 has no product record yet (drafted in products file); NCT06874335 is not yet a trial record in OnCo.
Connected
10Similar pages
- TrialA Study of GQ1010 in Subjects With Advanced Solid Tumors
Shares BHV-1510, TROP2, Antibody-drug conjugate (ADC).
- TrialTHOR
Shares FGFR3, Bladder & urothelial cancer.
- CompanyNucleix
- TreatmentCAN020
Shares TROP2, Antibody-drug conjugate (ADC).
- TreatmentCBB-120
Shares TROP2, Antibody-drug conjugate (ADC).
- TreatmentCTPH-03
Shares TROP2, Antibody-drug conjugate (ADC).
- BiomarkerFGFR3 alteration (mutation or fusion)
Shares FGFR3, Bladder & urothelial cancer.
- TreatmentBIO-106
Shares TROP2, Antibody-drug conjugate (ADC).
cancers
fronts
technologies
targets
drugs
companies
trials
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
biohaven.com · 2
ClinicalTrials.gov · 2
racap.com · 1
sec.gov · 1
A source that has moved or gone is reported by the weekly link check. /audit/